Diffusion-weighted magnetic resonance imaging as an alternative to positron emission tomography combined with computed tomography with 18F-fluorodeoxyglucose in patients with lymphomas: a literature review and clinical observations

Cover Page

Cite item

Full Text

Abstract

   Diffusion‑weighted magnetic resonance imaging may provide an alternative to traditional methods such as computed tomography and positron emission tomography / computed tomography with 18F‑fluorodeoxyglucose. The article analyzes not only the advantages of the method, but also the disadvantages and pitfalls that a diagnostician has to face. data from own studies on the use of whole‑body diffusion‑weighted magnetic resonance imaging in patients with lymphomas are presented.

About the authors

S. A. Alekseev

Main Military Clinical Hospital named after academician N. N. Burdenko, Ministry of Defense of Russia

Author for correspondence.
Email: alxvsrge@gmail.com
ORCID iD: 0000-0003-1329-8689

Sergey Anatolievich Alekseev

105094; 3 Gospital’naya Ploshchad’; Moscow

Russian Federation

V. N. Troyan

Main Military Clinical Hospital named after academician N. N. Burdenko, Ministry of Defense of Russia

ORCID iD: 0000-0002-8008-9660

105094; 3 Gospital’naya Ploshchad’; Moscow

Russian Federation

O. A. Rukavitsyn

Main Military Clinical Hospital named after academician N. N. Burdenko, Ministry of Defense of Russia

ORCID iD: 0000-0002-1309-7265

105094; 3 Gospital’naya Ploshchad’; Moscow

Russian Federation

A. A. Trefilov

Main Military Clinical Hospital named after academician N. N. Burdenko, Ministry of Defense of Russia

ORCID iD: 0000-0002-9885-5829

105094; 3 Gospital’naya Ploshchad’; Moscow

Russian Federation

References

  1. Rukavitsyn O.A., Troyan V.N., Kryukov E.V. et al. Radiologic diagnostics for blood system diseases. Moscow: GEOTAR­Media, 2021. 224 p. (In Russ.). doi: 10.33029/9704­6333­8­DIA­2021­1­224
  2. Rukavitsyn O.A., Udal’eva V.Yu., Ageeva T.A. et al. Hematology : National Guide. 2nd edn, revised and supplemented. Moscow: GEOTAR-­Media, 2024. 916 p. (In Russ.). doi: 10.33029/9704­8188­2­GEM­2024­1­916
  3. Glockner J.F., Hu H.H., Stanley D.W. et al. Parallel MR imaging: a user’s guide. Radiographics 2005;25(5):1279–97. doi: 10.1148/rg.255045202
  4. Ballon D., Watts R., Dyke J.P. et al. Imaging therapeutic response in human bone marrow using rapid whole­body MRI. Magn Reson Med 2004;52(6):1234–8. doi: 10.1002/mrm.20291
  5. De Bazelaire C., de Kerviler E. From multislice CT to whole­body biomarker imaging in lymphoma patients. Eur Radiol 2011;21(3):555–8. doi: 10.1007/s00330­010­2035­9
  6. Carbone P.P., Kaplan H.S., Musshoff K. et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res 1971;31(11):1860–1.
  7. Cheson B.D. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol 2015;4(1):5. doi: 10.3978/j.issn.2304­3865.2014.11.03
  8. Cheson B.D., Fisher R.I., Barrington S.F. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non­Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32(27):3059–68. doi: 10.1200/JCO.2013.54.8800
  9. Brenner D., Elliston C., Hall E. et al. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 2001;176(2):289–96. doi: 10.2214/ajr.176.2.1760289
  10. Mathews J.D., Forsythe A.V., Brady Z. et al. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ 2013;346:f2360. doi: 10.1136/bmj.f2360
  11. Jerusalem G., Beguin Y., Najjar F. et al. Positron emission tomography (PET) with 18F­fluorodeoxyglucose (18F­FDG) for the staging of low­grade non­Hodgkin’s lymphoma (NHL). Ann Oncol 2001;12(6):825–30. doi: 10.1023/a:1011169332265
  12. Townsend D.W. Multimodality imaging of structure and function. Phys Med Biol 2008;53(4):R1–39. doi: 10.1088/0031­9155/53/4/R01
  13. Kwee T.C., Takahara T., Ochiai R. et al. Whole­body diffusion-weighted magnetic resonance imaging. Eur J Radiol 2009;70(3):409–17. doi: 10.1016/j.ejrad.2009.03.054
  14. Darge K., Jaramillo D., Siegel M.J. Whole­body MRI in children: current status and future applications. Eur J Radiol 2008;68(2): 289–98. doi: 10.1016/j.ejrad.2008.05.018
  15. Wong F.C., Kim E.E. A review of molecular imaging studies reaching the clinical stage. Eur J Radiol 2009;70(2):205–11. doi: 10.1016/j.ejrad.2009.01.049
  16. Lin C., Luciani A., Itti E. et al. Whole­body diffusion­weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B­cell lymphoma. Eur Radiol 2010;20(8):2027–38. doi: 10.1007/s00330­010­1758­y
  17. Dudeck O., Zeile M., Pink D. et al. Diffusion­weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft­tissue sarcomas. J Magn Reson Imaging 2008;27(5):1109–13. doi: 10.1002/jmri.21358
  18. Wu X., Kellokumpu­Lehtinen P.L., Pertovaara H. et al. Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B­cell lymphoma – a pilot study: comparison with 2­-deoxy­2-­fluoro-­D­glucose­positron emission tomography/computed tomography. NMR Biomed 2011;24(10):1181–90. doi: 10.1002/nbm.1689
  19. Chen Y., Zhong J., Wu H., Chen N. The clinical application of whole­body diffusion­weighted imaging in the early assessment of chemotherapeutic effects in lymphoma: the initial experience. Magn Reson Imaging 2012;30(2):165–70. doi: 10.1016/j.mri.2011.09.019
  20. Gu J., Chan T., Zhang J. et al. Whole­body diffusion­weighted imaging: the added value to whole­body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol 2011;197(3):W384–91. doi: 10.2214/AJR.10.5692
  21. Stéphane V., Samuel B., Vincent D. et al. Comparison of PET­CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas. Eur J Radiol 2013;82(11):2011–7. doi: 10.1016/j.ejrad.2013.05.042
  22. Van Ufford H.M., Kwee T.C., Beek F.J. et al. Newly diagnosed lymphoma: initial results with whole­body T1-­weighted, STIR, and diffusion­weighted MRI compared with 18F­FDG PET/CT. AJR Am J Roentgenol 2011;196(3):662–9. doi: 10.2214/AJR.10.4743
  23. Padhani A.R., Koh D.M., Collins D.J. Whole­body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 2011;261(3):700–18. doi: 10.1148/radiol.11110474
  24. Le Bihan D., Poupon C., Amadon A., Lethimonnier F. Artifacts and pitfalls in diffusion MRI. J Magn Reson Imaging 2006;24(3):478–88. doi: 10.1002/jmri.20683
  25. Nasu K., Kuroki Y., Sekiguchi R. et al. Measurement of the apparent diffusion coefficient in the liver: is it a reliable index for hepatic disease diagnosis? Radiat Med 2006;24(6):438–44. doi: 10.1007/s11604­006­0053­y
  26. Koh D.M., Padhani A.R. Diffusion­weighted MRI: a new functional clinical technique for tumour imaging. Br J Radiol 2006;79(944):633–5. doi: 10.1259/bjr/29739265
  27. Connors J.M. State­of­the­art therapeutics: Hodgkin’s lymphoma. J Clin Oncol 2005;23(26):6400–8. doi: 10.1200/JCO.2005.05.016
  28. Eissa L., Abdel Razek A.A.K., Helmy E. Arterial spin labeling and diffusion­weighted MR imaging: utility in differentiating idiopathic orbital inflammatory pseudotumor from orbital lymphoma. Clin Imaging 2021;71:63–8. doi: 10.1016/j.clinimag.2020.10.057
  29. Eraky A.M., Beck R.T., Treffy R.W. et al. Role of advanced MR imaging in diagnosis of neurological malignancies: current status and future perspective. J Integr Neurosci 2023;22(3):73. doi: 10.31083/j.jin2203073
  30. Giraudo C., Simeone R., Fosio M. et al. Diagnostic value of PET/MR with DWI for Burkitt lymphoma. Diagnostics (Basel) 2021;11(10):1867. doi: 10.3390/diagnostics11101867
  31. Hwang S., Panicek D.M. Magnetic resonance imaging of bone marrow in oncology, Part 2. Skeletal Radiol 2007;36(11):1017–27. doi: 10.1007/s00256­007­0308­4
  32. Liu Y., Wang Y., Wang P., Yu Q. A retrospective study to evaluate the CT and MR imaging findings of non­Hodgkin’s lymphoma affecting the jaw bones. Oral Radiol 2022;38(4):509–16. doi: 10.1007/s11282­021­00582­y
  33. Sharma S., Leung W.H., Deqing P. et al. Osteonecrosis in children after allogeneic hematopoietic cell transplantation: study of prevalence, risk factors and longitudinal changes using MR imaging. Bone Marrow Transplant 2012;47(8):1067–74. doi: 10.1038/bmt.2011.234
  34. Siegel R.L., Miller K.D., Wagle N.S. et al. Cancer statistics, 2023. CA Cancer J Clin 2023;73(1):17–48. doi: 10.3322/caac.21763
  35. Thuy T.T.M., Trang N.T.H., Vy T.T. et al. Role of diffusion­weighted MRI in differentiation between benign and malignant anterior mediastinal masses. Front Oncol 2022;12:985735. doi: 10.3389/fonc.2022.985735
  36. Toledano­Massiah S., Luciani A., Itti E. et al. Whole­body diffusion­weighted imaging in Hodgkin lymphoma and diffuse large B­cell lymphoma. Radiographics 2015;35(3):747–64. doi: 10.1148/rg.2015140145
  37. Winzer R., Hoberück S., Zöphel K. et al. Diffusion-­weighted MRI for initial staging in Hodgkin’s lymphoma: comparison with FDG PET. Eur J Radiol 2020;123:108775. doi: 10.1016/j.ejrad.2019.108775

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.